Zhe Jiang Dayang Biotech Group Co., Ltd.

Equities

003017

CNE100004736

Commodity Chemicals

End-of-day quote Shenzhen S.E. 06:00:00 2024-05-16 pm EDT 5-day change 1st Jan Change
19.16 CNY +1.81% Intraday chart for Zhe Jiang Dayang Biotech Group Co., Ltd. -0.16% -21.22%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Zhejiang Xinzhichun Semiconductor Materials Co., Ltd. announced that it has received CNY 14.7143 million in funding from Zhe Jiang Dayang Biotech Group Co., Ltd. CI
Zhe Jiang Dayang Biotech Group Co., Ltd. Proposes Final Cash Dividend for 2023 CI
Tranche Update on Zhe Jiang Dayang Biotech Group Co., Ltd.'s Equity Buyback Plan announced on February 6, 2024. CI
Zhe Jiang Dayang Biotech Group Co., Ltd. announces an Equity Buyback for CNY 84 million worth of its shares. CI
Zhe Jiang Dayang Biotech Group Co., Ltd. authorizes a Buyback Plan. CI
Zhejiang Dayang Biotech Group Co., Ltd. Approves Interim Cash Dividend for the Year 2023, Payable on November 14, 2023 CI
Certain A Shares of Zhejiang Dayang Biology Technology Co.,Ltd. are subject to a Lock-Up Agreement Ending on 27-OCT-2023. CI
Zhejiang Dayang Biotech Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Zhejiang Dayang Biotech Group Co., Ltd. Approves Interim Cash Dividend for the Year 2023 CI
Zhejiang Dayang Biotech Group Co., Ltd. Announces the Profit Distribution Proposal for the First Half of 2023 CI
Zhejiang Dayang Biotech Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Fujian Shunyue Technology Co., Ltd. announced that it expects to receive CNY 96.672753 million in funding from Zhe Jiang Dayang Biotech Group Co., Ltd. CI
Zhejiang Dayang Biology Technology Co.,Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date Is 29 June 2023 CI
Dayang Biotech Vice Chairman Dies of Illness MT
Zhejiang Dayang Biology Technology Co.,Ltd. Approves Cash Dividend for the Year 2022 CI
Zhejiang Dayang Biology Technology Co.,Ltd. Proposes Cash Profit Distribution for 2022 CI
Zhejiang Dayang Biotech Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Zhejiang Dayang Biotech Sells Idle Properties MT
Zhejiang Dayang Biology Technology Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Zhejiang Dayang Biology Technology Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Zhejiang Dayang Biology Technology Co.,Ltd. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on July 08, 2022 CI
Tranche Update on Zhejiang Dayang Biology Technology Co.,Ltd.'s Equity Buyback Plan announced on November 26, 2021. CI
Zhejiang Dayang Biology Technology Co.,Ltd.'s Equity Buyback announced on November 26, 2021, has expired with 2,800,000 shares, representing 4.7% for CNY 88.09 million. CI
Zhejiang Dayang Biology Technology Co.,Ltd. Approves Final Cash Dividend for the Year 2021 CI
Zhejiang Dayang Biology Technology Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Chart Zhe Jiang Dayang Biotech Group Co., Ltd.
More charts
Zhejiang Dayang Biotech Group Co Ltd is a China-based company mainly engaged in the production and sales of chemical raw materials such as inorganic salts and veterinary raw materials. The Company's main products include potassium carbonate, potassium bicarbonate, amproline hydrochloride, 2-chloro-6-fluorobenzaldehyde, etc. Its products are used in food, pesticide, fertilizer, medicine and glass fields. The Company conducts its businesses within the Chinese market and to overseas markets.
Calendar
More about the company
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW